Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $14.8 million.

  • Vanda Pharmaceuticals' Net Cash Flow rose 63275.61% to $14.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.5 million, marking a year-over-year increase of 4754.96%. This contributed to the annual value of -$17.5 million for FY2025, which is 4754.96% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Net Cash Flow of $14.8 million as of Q4 2025, which was up 63275.61% from -$10.8 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Net Cash Flow ranged from a high of $219.1 million in Q1 2023 and a low of -$204.1 million during Q2 2023
  • Moreover, its 5-year median value for Net Cash Flow was -$4.7 million (2021), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Net Cash Flow surged by 507872.73% in 2022, and later crashed by 222423.14% in 2023.
  • Over the past 5 years, Vanda Pharmaceuticals' Net Cash Flow (Quarter) stood at $1.6 million in 2021, then skyrocketed by 5078.73% to $85.4 million in 2022, then plummeted by 155.61% to -$47.5 million in 2023, then surged by 104.25% to $2.0 million in 2024, then soared by 632.76% to $14.8 million in 2025.
  • Its Net Cash Flow stands at $14.8 million for Q4 2025, versus -$10.8 million for Q3 2025 and -$30.9 million for Q2 2025.